- Walgreens expanding scope of retail pharmacy experience and services heading into fiscal 2014
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Bloomberg: Greg Wasson joins thought leaders to discuss the state of health care in the United States
- CNNMoney sits down with Walgreens chief to discuss future of health care and what it means for pharmacy
- Walgreens, Rite Aid join outcry over Boston Rolling Stone cover
VALLEY FORGE, Pa. — AmerisourceBergen announced on Thursday that fourth quarter revenue rose 28.3% as it gains “strong momentum” heading into fiscal 2014.
“In our September quarter, we delivered strong results and successfully implemented the first phase of our new expanded contract with Walgreens,” stated Steven Collis, president and CEO. “Our performance in the quarter and the full year, combined with the opportunities we have on the horizon, drive strong momentum heading into fiscal 2014. Our innovative programs and services, strategic relationship with Walgreens and Alliance Boot GmbH, operational excellence and financial discipline give us great confidence in our ability to continue to deliver tremendous value to our customers, suppliers, associates and shareholders.”
As reported by Drug Store News, AmerisourceBergen and Walgreens officially announced in early September the launch of a 10-year relationship to distribute pharmaceuticals to more than 8,100 Walgreens locations across the country.
During the quarter ended Sept. 30, revenue totaled $24.5 billion, up 28.3% compared with the year-ago period. This boost reflects a 34% increase in AmerisourceBergen Drug Corp. revenue, and a 12% increase in AmerisourceBergen Specialty Group revenue.
Operating income during the quarter totaled $318.6 million, flat versus the year-ago period.
Adjusted diluted earnings per share from continuing operations were up 2.6% to 79 cents in the quarter compared with 77 cents in the previous fiscal year’s fourth quarter.
For fiscal year 2013, adjusted earnings per share from continuing operations were $3.14, up 6.1% compared with the prior year GAAP diluted earnings per share. Revenue totaled $88 billion, up 12.7%. Operating income decreased 2.9%.